ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional

Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment

ClinicalTrials.gov ID: NCT03847428

Public ClinicalTrials.gov record NCT03847428. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 21, 2026, 12:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation

Study identification

NCT ID
NCT03847428
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
AstraZeneca
Industry
Enrollment
908 participants

Conditions and interventions

Interventions

  • Bevacizumab Drug
  • Durvalumab Drug
  • Placebo Other

Drug · Other

Eligibility (public fields only)

Age range
18 Years to 150 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 28, 2019
Primary completion
May 28, 2026
Completion
May 30, 2027
Last update posted
Mar 5, 2026

2019 – 2027

United States locations

U.S. sites
34
U.S. states
23
U.S. cities
34
Facility City State ZIP Site status
Research Site Birmingham Alabama 35233
Research Site Mobile Alabama 36604
Research Site Phoenix Arizona 85054
Research Site Costa Mesa California 92627
Research Site La Jolla California 92093-0698
Research Site Long Beach California 90806
Research Site Orange California 92868
Research Site Sacramento California 95817
Research Site Washington D.C. District of Columbia 20007
Research Site Miami Florida 33176
Research Site Tampa Florida 33606
Research Site Honolulu Hawaii 96819
Research Site Chicago Illinois 60637
Research Site Westwood Kansas 66205
Research Site Louisville Kentucky 40206
Research Site Shreveport Louisiana 71103
Research Site Detroit Michigan 48201
Research Site Grand Rapids Michigan 49503
Research Site Rochester Minnesota 55905
Research Site Omaha Nebraska 68198
Research Site New Brunswick New Jersey 08903
Research Site Albuquerque New Mexico 87109
Research Site New York New York 10021
Research Site Stony Brook New York 11794
Research Site Durham North Carolina 27710
Research Site Winston-Salem North Carolina 27157
Research Site Cleveland Ohio 44106
Research Site Philadelphia Pennsylvania 19104
Research Site Pittsburgh Pennsylvania 15212
Research Site Spartanburg South Carolina 29303
Research Site Knoxville Tennessee 37916
Research Site Memphis Tennessee 38104
Research Site Dallas Texas 75216
Research Site Madison Wisconsin 53715

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 183 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03847428, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 5, 2026 · Synced May 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03847428 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →